Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Wave’s challenge to Sarepta in Duchenne falls flat

Shares in the company down more than 50%

Roche Basel Switzerland

Roche to close $4.3bn Spark deal after FTC clearance

Comes on the heels of CMA green light

- PMLiVE

GSK files anti-BCMA drug for myeloma after second trial win

Important drug for GSK as it rebuilds R&D pipeline

- PMLiVE

Pharma’s race to digital

Federico Marchisio and Lorraine WaltersAs digital tools and technologies become ever more central to our lives they are increasingly being used to diagnose, treat and manage disease. Wearables are moving...

- PMLiVE

Entrepreneurial Winning Women

An executive education programme that supports women founders who have built profitable small companies

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Silos – a reflection on the second birthday of Porterhouse Insights

After another exciting year, Fabrice Allum, Managing Director at Porterhouse Insights, reflects on the benefits of cross-functional working for our pharmaceutical clients

Porterhouse Medical Group

- PMLiVE

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

Drug is on course for blockbuster sales

- PMLiVE

UK’s CMA clears Roche’s $4.3bn takeover of Spark

Roche first announced deal in February

- PMLiVE

Roche’s Tecentriq combo scores in first-line melanoma

Plans to file treatment with health authorities on strength of data

- PMLiVE

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent

- PMLiVE

Novartis ditches oral asthma drug after disappointing phase 3 readout

Bad news for Gossamer’s would-be rival DP2 antagonist

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links